Last reviewed · How we verify
Select DMTs other than ozanimod
Select DMTs other than ozanimod is a Small molecule drug developed by Bristol-Myers Squibb. It is currently in Phase 2 development.
At a glance
| Generic name | Select DMTs other than ozanimod |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients
- A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Select DMTs other than ozanimod CI brief — competitive landscape report
- Select DMTs other than ozanimod updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about Select DMTs other than ozanimod
What is Select DMTs other than ozanimod?
Select DMTs other than ozanimod is a Small molecule drug developed by Bristol-Myers Squibb.
Who makes Select DMTs other than ozanimod?
Select DMTs other than ozanimod is developed by Bristol-Myers Squibb (see full Bristol-Myers Squibb pipeline at /company/bristol-myers-squibb).
What development phase is Select DMTs other than ozanimod in?
Select DMTs other than ozanimod is in Phase 2.